2. Cell Cycle/DNA Damage Epigenetics Cytoskeleton Immunology/Inflammation
  3. HDAC Collagen Interleukin Related Microtubule/Tubulin
  4. GV-001

GV-001 is a selective and orally active HDAC6 inhibitor with an IC50 of 1.18 nM against HDAC6. GV-001 selectively enhances α-tubulin acetylation, reduces sIL-6 and Collagen I levels, suppresses renal cyst growth, and upregulates PC1 expression. GV-001 can be used for the study of autosomal dominant polycystic kidney disease (ADPKD).

For research use only. We do not sell to patients.

GV-001

GV-001 Chemical Structure

CAS No. : 3082707-76-1

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

GV-001 Related Antibodies

Top Publications Citing Use of Products

View All HDAC Isoform Specific Products:

View All Isoforms
HDAC HDAC1 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HDAC10 HDAC11 HD1 HD2

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

GV-001 is a selective and orally active HDAC6 inhibitor with an IC50 of 1.18 nM against HDAC6. GV-001 selectively enhances α-tubulin acetylation, reduces sIL-6 and Collagen I levels, suppresses renal cyst growth, and upregulates PC1 expression. GV-001 can be used for the study of autosomal dominant polycystic kidney disease (ADPKD)[1].

IC50 & Target[1]

HDAC6

1.18 nM (IC50)

IL-6

 

Collagen I

 

α-Tubulin

 

In Vitro

GV-001 (6a) (2 h) potently and selectively inhibits recombinant human HDAC6 with an IC50 of 1.18 nM, showing 1991-fold selectivity over HDAC1 and 247-fold selectivity over HDAC8[1].
GV-001 (0.00152-30 μM; 16 h) selectively upregulates acetylated α-tubulin in HepG2 cells with an IC50 of 0.19 μM, showing 24-fold selectivity over acetylated histone H3 (IC50 = 4.46 μM)[1].
GV-001 (370 nM-10 μM; 48 h) modulates key inflammatory, fibrotic, and tissue remodeling biomarkers in human primary cell-based MyoF and REMyoF fibrosis models at noncytotoxic concentrations[1].
GV-001 (0.1-100 μM; 14 days) potently inhibits cyst formation in a 3D in vitro human ADPKD model, with IC50 values of 0.42 μM for cyst viability, 2.22 μM for cyst number, 0.92 μM for total cyst area, and 2.38 μM for average cyst size, without cytotoxicity at active concentrations[1].
GV-001 (0.001-100 μM; 12 days) potently reduces established cyst growth in a 3D in vitro human ADPKD model, with IC50 values of 8.36 μM for cyst viability, 13.3 μM for cyst number, 10.8 μM for total cyst area, and 18.5 μM for average cyst size[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

GV-001 Related Antibodies

Western Blot Analysis[1]

Cell Line: HepG2 cells
Concentration: 0.00152, 0.00457, 0.0137, 0.0412, 0.123, 0.37, 1.11, 3.33, 10, 30 μM
Incubation Time: 16 h
Result: Induced dose-dependent upregulation of acetylated α-tubulin with an IC50 of 0.19 μM.
Upregulated acetylated histone H3 with an IC50 of 4.46 μM.
Resulted in a 24-fold selectivity for α-tubulin acetylation over histone H3 acetylation.
Parmacokinetics
Species Dose Route C0 T1/2 AUC0-t AUC0-∞ Cmax Tmax Bioavailability T1/2 (Plasma) AUC0-∞ (Plasma)
Rat[1] 1 mg/kg i.v. 559 ng/mL 0.173 h 98.5 ng·h/mL 99.8 ng·h/mL / / / / /
Rat[1] 30 mg/kg p.o. / 2.94 h 1018 ng·h/mL 1087 ng·h/mL 480 ng/mL 0.250 h 36 % / /
Rat[1] 30 mg/kg p.o. / / / / / / / 3.90 h 997 ng·h/mL
Mice[1] 1 mg/kg i.v. 1222 ng/mL 0.200 h 184 ng·h/mL 184 ng·h/mL / / / / /
Mice[1] 30 mg/kg p.o. / 2.49 h 643 ng·h/mL 694 ng·h/mL 635 ng/mL 0.250 h 13 % / /
Mice[1] 60 mg/kg p.o. / 5.70 h 1408 ng·h/mL 2561 ng·h/mL 834 ng/mL 0.250 h 13 % / /
In Vivo

GV-001 (6a) (60-120 mg/kg; p.o.; daily; 14 days) significantly reduces cyst progression (with cystic index reductions to 22.7% and 20.7%, respectively) and increases PC1 expression in a transgenic ADPKD mouse model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 Tg(Ubi-emGFP Pkd1miRNA)1SJi/Narl transgenic mice (males and females, 14 days old at study start, stable Pkd1 knockdown via miRNA expression)[1]
Dosage: 60 mg/kg; 120 mg/kg
Administration: p.o.; daily; 14 days
Result: Reduced the average kidney-to-body weight ratio to 3.4% and reduced the cystic index to 22.7%.
Reduced the average kidney-to-body weight ratio to 3.2% and reduced the cystic index to 20.7%.
Increased PC1 positive area.
Molecular Weight

309.32

Formula

C17H15N3O3
CAS No.
SMILES

O=C(NO)C1=CC=C(CC(N2C)=NC3=C(C=CC=C3)C2=O)C=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

GV-001 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

GV-0013082707-76-1GV001GV 001HDACCollagenInterleukin RelatedMicrotubule/TubulinHistone deacetylasesILCollagen IsIL-6HepG2 cellsHDAC6transgenic ADPKD mouse modelautosomal dominant polycystic kidney diseaseREMyoFPC1MyoFratsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
GV-001
Cat. No.:
HY-182904
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.